Oncology NEWS Today Blog Vol 18 No 9

Follicular lymphoma vaccine finally makes good with prolonged disease-free survival

September 22, 2009

After almost a decade of research and two trials of a follicular lymphoma vaccine with negative results, a study of a personalized idiotype vaccine has achieved positive results. BiovaxID prolonged median disease-free survival by more than a year in a subset of patients who maintained complete remission after one year of chemotherapy and then received the vaccine.

EphA2-targeted therapy strikes directly at cells of ovarian cancer

September 21, 2009

M.D. Anderson Cancer Center scientists have targeted a protein that is overexpressed in ovarian cancer cells and used it as a molecular homing mechanism to deliver chemotherapy in preclinical models. The protein, EphA2, is attractive for molecularly targeted therapy because its overexpression is associated with poor prognosis, according to Anil K. Sood, MD, and colleagues.

Inflammation linked to fatigue after radiotherapy

September 21, 2009

Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to researchers from the University of California, Los Angeles.